BioSpace News Archive

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), today announced the award of the first U.S. patent for its revolutionary Ultra Shear Technology™ (UST™) platform entitled “System for High Pressure, High Shear Processing of Fluids.

Valley Urogynecology Associates, Ltd has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005114/en/ (Photo: Solace Therapeu

Freedman Urology has enrolled their first patient in the VESAIR Clinical TRIAL. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

Magnolia Medical Technologies, Inc. today announced the appointment of Gary V. Doern, Ph.D., Professor Emeritus of Pathology, University of Iowa Carver College of Medicine to its Medical & Scientific Advisory Board (MSAB).

Berenson Cancer Center, a world class multiple myeloma cancer research, diagnostic and treatment center has completed an extensive rebranding effort in response to accelerated company growth and a renewal of its corporate vision.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with pediatric cancers, solid tumors and other cancers, today reported its corporate and financial results for the third quarter ended September 30, 2020. Recent Business and Corporate Events: Ewing sarcoma Phase 1/2 clinical trial is completing dose escalation to establish maximum tolerated dose (M

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3 rd Annual Evercore ISI HealthCONx Conference. Stifel 2020 Virtua

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2020 and certain business highlights. The Company’s net loss applicable to common shareholders for the three months ended September 30, 2020 was $2.3 million. As of September 30, 2020, cash and cash

Surgalign Holdings, Inc., a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, reported operating results for the third quarter of 2020.